Study explains why certain immunotherapies do

An MIT study reveals a possible explanation for why checkpoint blockade inhibitors don’t work well for some patients whose tumors have a high mutational burden.

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Davidh Koch ,Peter Westcott ,Tyler Jacks ,Isidro Cortes Ciriano ,Howard Hughes Medical Institute ,European Bioinformatics Institute ,Koch Institute For Cancer Research ,Cold Spring Harbor Laboratory ,Us National Cancer Institute ,Koch Institute ,Bioinformatics Institute ,Koch Institute Support ,Cancer Institute ,Damon Runyon Fellowship ,